Kyle Wilks
Net worth: 12 181 $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Seckler | M | 59 | 1 years | |
Scott Rogow | M | - | 2 years | |
Lana Newishy | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Joseph Martinez | M | - | - | |
Dennis Nelson | M | 51 | 1 years | |
Robert Davis | M | 57 | 10 years | |
Kyle Appleby | M | 48 | 1 years | |
Roger Greene | M | 69 | 1 years | |
Natalia Vakhitova | F | 38 | 1 years | |
Fang-Tyan Chen | M | 74 | 11 years | |
Uma Chowdhry | M | 76 | 4 years | |
John Greisch | M | 69 | 7 years | |
Jane Kiernan | F | 63 | 2 years | |
Melissa Polesky-Meyrowitz | F | 35 | 1 years | |
Robert Felicelli | M | - | - | |
Royston Glasspool | M | 61 | 3 years | |
Francois Lebel | M | 72 | 1 years | |
Robert J. Weiland | M | 64 | 7 years | |
Marcus Schabacker | M | 60 | - | |
Hartmut Ehrlich | M | - | 7 years | |
Kenneth Watkinson | M | 55 | 2 years | |
Devdatt Kurdikar | M | 56 | 2 years | |
Ellen K. McIntosh | F | - | - | |
Irina P. Konstantinovsky | F | 54 | 5 years | |
Meredith S. Manning | F | - | 2 years | |
Stacie Phillips | F | 50 | - | |
Jacques Suzanne | F | 53 | - | |
Amy Pott | F | 47 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 3 years |
Christopher Miskel | M | 49 | 4 years | |
Anila Lingamneni | F | 57 | 7 years | |
Douglas Losordo | M | 65 | 2 years | |
Jaren Madden | F | - |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 1 years |
Camille Farhat | M | 55 | 5 years | |
Gary Sender | M | 62 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 6 years |
Jean-Luc Butel | M | 67 | 3 years | |
Bruce H. McGillivray | M | 68 | 8 years | |
Peter Arduini | M | 59 | 5 years | |
Karenann Terrell | F | 62 | 4 years | |
Richard Mejia | M | 76 | 1 years | |
Joy Amundson | F | 69 | 6 years | |
Norbert Riedel | M | 66 | 15 years | |
Paul Martin | M | 66 | 9 years | |
Gerald Lema | M | 63 | 10 years | |
Lina Karlsson | M | 51 | 5 years | |
Sven Anders Ullman | M | 68 | 1 years | |
Omar Khalil | M | - | 6 years | |
Ludwig Hantson | M | 61 | 5 years | |
Randy Berholtz | M | 63 | 1 years | |
Jennifer Schranz | M | 59 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | 4 years |
Thomas Sabatino | M | 65 | 14 years | |
Kate C. Liebelt | F | - | 3 years | |
Stuart Paul | M | 64 | 2 years | |
Parth Chakrabarti | M | - | 3 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 49 | 92.45% |
United Kingdom | 4 | 7.55% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Kyle Wilks
- Personal Network